作者
Camille Verry, Sandrine Dufort, Julie Villa, Marylaure Gavard, Carole Iriart, Sylvie Grand, Julie Charles, Benoit Chovelon, Jean-Luc Cracowski, Jean-Louis Quesada, Christophe Mendoza, Lucie Sancey, Audrey Lehmann, Florence Jover, Jean-Yves Giraud, François Lux, Yannick Crémillieux, Stephen McMahon, Petrus J Pauwels, Daniel Cagney, Ross Berbeco, Ayal Aizer, Eric Deutsch, Markus Loeffler, Géraldine Le Duc, Olivier Tillement, Jacques Balosso
发表日期
2021/7/1
期刊
Radiotherapy and Oncology
卷号
160
页码范围
159-165
出版商
Elsevier
简介
Background and purpose
Brain metastasis impacts greatly on patients’ quality of life and survival. The phase I NANO-RAD trial assessed the safety and maximum tolerated dose of systemic administration of a novel gadolinium-based nanoparticle, AGuIX, in combination with whole brain radiotherapy in patients with multiple brain metastases not suitable for stereotactic radiotherapy.
Materials and methods
Patients with measurable brain metastases received escalating doses of AGuIX nanoparticles (15, 30, 50, 75, or 100 mg/kg intravenously) on the day of initiation of WBRT (30 Gy in 10 fractions) in 5 cohorts of 3 patients each. Toxicity was assessed using NCI Common Terminology Criteria for Adverse Events v4.03.
Results
Fifteen patients with 354 metastases were included. No dose-limiting toxic effects were observed up to AGuIX 100 mg/kg. Plasma elimination half-life of AGuIX was similar for all groups (mean 1.3 h …
学术搜索中的文章
C Verry, S Dufort, J Villa, M Gavard, C Iriart, S Grand… - Radiotherapy and Oncology, 2021